Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-™T) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC

1 year ago 33
Read Entire Article
  1. Homepage
  2. Finance
  3. Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-™T) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC

Related

Ukraine drones kill four in Russia, Moscow faces biggest attack in over a year

Ukraine drones kill four in Russia, Moscow faces biggest att...

30 minutes ago 1
Earnings call transcript: Tata Steel Q4 2026 sees strong financial performance

Earnings call transcript: Tata Steel Q4 2026 sees strong fin...

30 minutes ago 1
Palestinian leader’s son wins role in Abbas’ party, official says

Palestinian leader’s son wins role in Abbas’ party, official...

30 minutes ago 1

Trending

1. drone strike abu dhabi
2. us china trade boards
3. dividend
4. dc vs rr
5. alex cooper
6. adu housing
7. wolves vs fulham
8. leeds vs brighton
9. everton vs sunderland
10. brentford vs palace

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

1 year ago 733
What is Tren de Aragua, the Venezuelan gang targeted by Trump?

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

1 year ago 594
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

1 year ago 460
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

1 year ago 458
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

1 year ago 407
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2026. All rights are reserved